drug delivery

News
Takeda tries again with subcutaneous Entyvio

Takeda tries again with subcutaneous Entyvio

More than three years after it was first rejected by the FDA, Takeda's subcutaneous (SC) formulation of Entyvio has been resubmitted as a maintenance therapy for ulcerativ

News
Oramed_pill_image

Phase 3 trial dashes Oramed's oral insulin hopes

Oramed Pharma has conceded defeat in its attempt to bring an oral formulation of insulin to market for people with type 2 diabetes, after its ORMD-0801 candidate missed the mark in a phase